SCHEMBL19586802

SCHEMBL19586802

CNC(CN)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.53
GAA P10253 1/20 0.51
MAPT P10636 1/20 0.51
MAOA P21397 1/20 0.51
RAB9A P51151 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
ALOX5 P09917 1/20 0.49
BCHE P06276 2/20 0.49
LMNA P02545 1/20 0.49
CYP1A2 P05177 1/20 0.49
PTGS1 P23219 1/20 0.49
SLC6A2 P23975 1/20 0.49
CYP2C19 P33261 1/20 0.49
PTGS2 P35354 1/20 0.49
SLC6A3 Q01959 1/20 0.49
HIF1A Q16665 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
LTA4H P09960 2/20 0.48
ALDH1A1 P00352 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28072063 0.86 BCHE (0.50) MAOBGAAMAPTMAOARAB9A
SCHEMBL11624061 0.81 C5AR1 (0.46) MAPTSMN1; SMN2L3MBTL1
SCHEMBL5326015 0.80 BCHE (0.58) MAOBGAAMAPTMAOARAB9A
SCHEMBL10426966 0.80 ACACB (0.58) MAOBGAAMAPTMAOARAB9A
SCHEMBL11080230 0.79 MAOB (0.50) MAOBGAAMAPTMAOARAB9A
SCHEMBL9878279 0.79 MAOB (0.61) MAOBGAAMAPTMAOARAB9A
SCHEMBL11074823 0.79 MAOB (0.61) MAOBGAAMAPTMAOARAB9A
SCHEMBL7043509 0.79 NPC1 (0.48) MAOBRAB9ASMN1; SMN2ALOX5LMNA
Hydrochloric Acid SCHEMBL5878046 0.78 MAOB (0.60) MAOBGAAMAPTMAOARAB9A
Hydrochloric Acid SCHEMBL7913851 0.78 ACACB (0.56) MAOBGAAMAPTMAOARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12048747-B2 Substituted piperidine Degronimers for Target Protein degradation C4 THERAPEUTICS, INC. (US) 2024-07-30 US disclosed
US-20220313827-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2022-10-06 US disclosed
EP-3455219-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2019-03-20 EP disclosed
WO-2017197051-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2017-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220313827-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, NEDD4 MAOB 3490/4885GAA 815/4885MAPT 2328/4885
US-12048747-B2 Substituted piperidine Degronimers for Target Protein degradation GID4, RNF5, UBE3C MAOB 3071/4885GAA 1042/4885MAPT 2093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.